Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

X.l

X - Systemic/Distant conditions, syndromes and reactions

Myopathy-Myositis-Polymyositis (see also under Xba)

Last update 26/02/2019

Including acute myositis, rhabdomyolysis, a mimic of autoimmune anti-Jo1-positive polymyositis/dermato-polymyositis and necrotizing autoimmune myopathy. Respiratory muscles can be involved (PMID 12904161): see specifically under IXac

Causative drugs

31

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Adalimumab
I.a
I.b
I.c
I.e
I.g
I.n
I.x
I.aa
II.e
III.a
III.d
IV.a
VI.d
VI.m
IX.j
X.b
X.d
X.e
X.l
X.m
X.u
XII.a
XII.s
XVI.e
XVI.k
XIX.a
XIX.d
XIX.f
XX.a
XX.b
XX.c
XX.e
XX.f
XX.g
XX.y
XX.z
Afatinib
I.a
IV.x
VI.a
X.l
XII.q
XVI.b
XIX.aq
Betamethasone
X.l
XII.x
Bezafibrate
X.l
Breast implants - Augmentation mammaplasty (w/wo evidence for leakage/rupture)
I.a
I.c
I.o
I.am
I.an
II.u
III.a
VI.a
VI.w
VI.x
VIII.a
VIII.e
VIII.o
X.e
X.j
X.l
X.m
X.o
X.s
X.u
X.af
XII.c
XVI.k
XVI.ax
XVI.bk
XVII.c
XIX.af
XIX.aj
XIX.bq
XIX.cx
XXI.f
XXI.h
XXI.i
Cathinones, synthetic ('Bath salts')
X.l
XI.o
XII.g
XII.y
XII.aj
Cobimertinib
IX.v
X.l
Cocaine
I.c
I.d
I.e
I.u
I.aa
II.a
II.b
III.a
III.b
III.c
III.n
IV.a
IV.b
IV.g
V.a
V.c
V.l
V.p
V.q
V.w
V.ai
V.aj
V.al
V.aq
VI.f
VI.ac
VII.a
VII.b
VII.l
VIII.h
IX.k
IX.o
X.f
X.j
X.l
X.o
X.q
X.u
X.w
X.z
X.ae
X.af
X.au
XI.b
XI.k
XI.l
XI.o
XI.ab
XI.au
XII.a
XII.f
XII.g
XII.h
XII.n
XII.aa
XII.ag
XII.ah
XII.al
XII.ar
XIV.b
XVI.k
XIX.b
XIX.r
XIX.t
XIX.v
XIX.ac
XIX.cz
XX.b
COVID19 (SARS-CoV2) vaccination/vaccine
I.a
I.b
I.c
I.z
I.ae
I.az
I.bd
II.b
II.e
III.a
III.m
IV.a
IV.c
VII.a
VII.b
VII.ab
IX.r
IX.y
IX.ab
X.b
X.d
X.f
X.h
X.j
X.l
X.o
X.u
X.al
X.bg
X.bh
X.bi
X.bk
XI.b
XII.a
XII.c
XII.d
XII.e
XII.f
XII.h
XII.i
XII.l
XII.n
XII.r
XII.u
XII.ak
XII.bi
XVI.b
XVI.c
XVI.ba
XVIII.a
XVIII.c
XIX.a
XIX.d
Durvalumab
I.a
I.c
IV.a
IV.j
IV.w
IV.x
IX.r
X.l
XII.c
XII.d
XVI.v
XVI.al
XIX.d
XIX.j
XIX.co
XXIII.e
Etanercept
I.a
I.e
I.g
I.n
I.r
I.x
I.z
III.a
IV.a
V.a
VI.d
VI.f
VI.m
VII.a
VII.d
VIII.a
IX.q
X.b
X.d
X.e
X.f
X.l
X.m
X.o
X.u
X.ae
X.at
XI.aa
XII.d
XIX.a
XIX.d
XIX.f
XIX.bx
XX.a
XX.b
XX.f
XX.g
XX.h
XX.aa
Fenofibrate
X.l
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.v
I.w
I.x
I.z
I.ab
I.ae
I.ak
I.ay
II.b
II.e
III.m
IV.a
IV.d
IV.t
IV.x
IV.af
IV.ag
V.g
VI.a
VI.i
VI.t
VII.a
VII.b
VIII.a
IX.a
IX.d
IX.r
IX.ab
IX.ac
X.a
X.c
X.d
X.e
X.f
X.i
X.j
X.l
X.m
X.o
X.p
X.u
X.w
X.ao
X.ap
X.ax
X.az
X.bj
XI.l
XI.v
XI.ad
XI.ar
XI.as
XI.av
XII.a
XII.c
XII.d
XII.f
XII.h
XII.n
XII.o
XII.s
XII.t
XII.ak
XII.az
XII.bd
XVI.k
XVI.v
XVI.w
XVI.bj
XVI.bk
XVI.bv
XVIII.a
XVIII.b
XVIII.c
XIX.a
XIX.b
XIX.d
XIX.e
XIX.f
XIX.j
XIX.o
XIX.x
XIX.ae
XIX.al
XIX.bx
XIX.co
XIX.cr
XIX.cv
XX.b
XX.c
XX.e
XX.g
XX.q
XX.r
Infliximab
I.a
I.b
I.c
I.d
I.e
I.g
I.x
I.z
II.e
III.a
IV.a
VI.a
VI.d
VII.a
VII.d
X.a
X.b
X.d
X.e
X.f
X.i
X.j
X.l
X.m
X.u
X.aj
X.at
XII.c
XII.d
XII.r
XII.bt
XVI.b
XIX.a
XIX.o
XIX.bo
XX.b
XX.c
XX.d
XX.e
XX.f
XX.g
XX.h
XX.n
XX.o
XX.q
XX.r
XX.x
XX.y
XX.ab
Interferon alpha/beta
I.a
I.b
I.e
I.g
I.n
I.w
I.z
II.a
II.e
IV.a
IV.r
IV.ab
V.a
VI.a
VII.b
VII.d
VII.f
VIII.a
VIII.e
X.b
X.c
X.d
X.f
X.l
X.m
X.w
XI.l
XIX.a
XIX.d
XIX.f
XIX.k
XIX.o
XX.g
Loading more…